Identification of Novel Anthracycline Resistance Genes and Their Inhibitors.

Onat Kadioglu,Thomas Efferth,Edmond Fleischer,Mohamed Elbadawi

doi:10.3390/ph14101051

Onat Kadioglu, Thomas Efferth + Show 2 more

Open Access

https://doi.org/10.3390/ph14101051

Copy DOI

Abstract

Differentially expressed genes have been previously identified by us in multidrug-resistant tumor cells mainly resistant to doxorubicin. In the present study, we exemplarily focused on some of these genes to investigate their causative relationship with drug resistance. HMOX1, NEIL2, and PRKCA were overexpressed by lentiviral-plasmid-based transfection of HEK293 cells. An in silico drug repurposing approach was applied using virtual screening and molecular docking of FDA-approved drugs to identify inhibitors of these new drug-resistant genes. Overexpression of the selected genes conferred resistance to doxorubicin and daunorubicin but not to vincristine, docetaxel, and cisplatin, indicating the involvement of these genes in resistance to anthracyclines but not to a broader MDR phenotype. Using virtual drug screening and molecular docking analyses, we identified FDA-approved compounds (conivaptan, bexarotene, and desloratadine) that were interacting with HMOX1 and PRKCA at even stronger binding affinities than 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethenone and ellagic acid as known inhibitors of HMOX1 and PRKCA, respectively. Conivaptan treatment increased doxorubicin sensitivity of both HMOX1- and PRKCA-transfected cell lines. Bexarotene treatment had a comparable doxorubicin-sensitizing effect in HMOX1-transfected cells and desloratadine in PRKCA-transfected cells. Novel drug resistance mechanisms independent of ABC transporters have been identified that contribute to anthracycline resistance in MDR cells.

Highlights

A drug repurposing approach was applied to identify potential inhibitors of these novel drug resistance mechanisms in an attempt to overcome drug resistance conferred by these genes
2, heme oxygenase 1 (HMOX1), NEIL2, of and PRKCA plasmidand constructs were transpotentially increases effectiveness chemotherapy improves clinical out fected into HEK293 cells
Of HMOX1, NEIL2,mechanisms and PRKCA was for the transfected cells, and β-actin used as a loading control

Summary

Introduction

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Drug resistance is frequently multifactorial in nature, but the full complexity of mechanisms and genetic alterations has been rarely addressed. Is linked with drug efflux pumps such as P-glycoprotein, but other mechanisms are involved [1,2,3,4]. Drugs accumulate in cancer cells by various mechanisms, such as diffusion, drug transport, and endocytosis. Each of these mechanisms possesses physiological significance based on detailed uptake studies in drug-resistant mutants [5]

Methods

Results

Discussion

Conclusion